Myasthenia gravis
RSS feedCharacteristics of and response to treatment for double seronegative myasthenia gravis
A retrospective Canadian study of 80 people with double-seronegative myasthenia for anti-RACh and anti-MuSK antibodies, compared with 73 people with myasthenia for anti-RACh antibodies, showed that : the initial proportion of people with ocular forms (46.3%) was significantly higher in the double-seronegative group than in the anti-RACh myasthenia group; the Myasthenia Gravis Impairment Index (MGII) … [Read more]
Promising initial results for CAR-T RNA cells in myasthenia gravis
The MG-001 trial is evaluating Descartes-08 CAR-T cells from Cartesian Therapeutics in the United States. These are autologous T lymphocytes genetically modified, not by DNA but by RNA, to target the B lymphocyte maturation antigen (BCMA) expressed on the surface of plasma cells. The first two parts of the trial, in 14 adults with a … [Read more]
Myasthenia gravis and innovative therapies: a study provides a critical overview of the data in the literature
Italian researchers have compiled recent data from the literature on the efficacy of new treatments for myasthenia gravis, in particular complement inhibitors and fetal immunoglobulin receptor (FcRn) blockers. A Cochrane-type approach was used, resulting in a simple meta-analysis and a network meta-analysis, The observation windows for product efficacy were significantly different (26 weeks for eculizumab … [Read more]
Cross-sectional study of neuromuscular fatigue in autoimmune myasthenia – Interview with Simone Birnbaum
Simone Birnbaum, a researcher at the Neuromuscular Physiology and Evaluation Laboratory directed by Jean-Yves Hogrel (NIC, Institute of Myology) has just published an article assessing neuromuscular fatigue in persons with Myasthenia gravis in the journal Clinical Neurophysiology. Interview with Simone Birnbaum. What was the aim of the study? Myasthenia gravis (MG) is a rare disease characterized by … [Read more]
Firdapse® in Myasthenia Gravis too?
3,4-diaminopyridine or amifampridine (Firdapse®) is already indicated in some myasthenic syndromes, congenital or autoimmune (Lambert-Eaton). In the past, case reports had alerted to the possible efficacy of this drug in myasthenia gravis as well. The results of an open-label clinical trial conducted in Italy in 15 adults with anti-acetylcholine receptor (AChR) myasthenia gravis support these … [Read more]
